Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at MedStar Washington Hospital Center, discusses final overall survival (OS) analysis from the CLEOPATRA study of first-line pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer.
Median OS was 40.8 months in the placebo arm and 56.5 months in the pertuzumab arm — a different of 15.7 months. This is truly a remarkable improvement, Swain says.
Monoclonal antibodies have changed the trajectory of the disease in many patients with HER2-positive metastatic breast cancer, Swain says, and they are now able to live fairly normal lives.
<<< View more from the 2014 ESMO Congress